1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Decision Time For Janssen’s Talquetamab & 14 Other Products, But MSD Withdraws Lagevrio Filing

 
• By Neena Brizmohun

A bumper crop of products are up for an opinion this week by the European Medicines Agency’s human medicines committee, the CHMP, as to whether they should be approved in the EU.

European Flags in front of the European Commission Headquarters building in Brussels, Belgium
CHMP opinions on drugs are sent to the European Commission for a legally binding decision • Source: Shutterstock

The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing approval for 15 new products, including talquetamab, Janssen’s investigational bispecific antibody for treating patients with relapsed or refractory multiple myeloma (RRMM).

Pfizer’s respiratory syncytial virus vaccine for older adults, and the company’s ritlecitinib for treating alopecia areata in adults and adolescents, are also among the 15 products, according to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.